Sun Pharma Financial Statements

Sun Pharma (SUNPHARMA) reported revenue of ₹584.62B in FY2026 with net income of ₹115.09B. Total assets stood at ₹1,087.85B. Net worth was ₹835.70B (₹83,570 Cr) and free cash flow was ₹88.10B.

Sun Pharma Income Statement

Hover the chart icon for year-over-year change.

FY 2025 – FY 2026

Item	Chart	2025	2026
Revenue		525.78B	584.62B
Cost of Rev. Cost of Revenue		-107.47B	-115.44B
Gross Profit		418.31B	469.18B
SGA Sales, General & Admin		-267.45B	-291.87B
Op. Income Operating Income		125.11B	147.94B
PBT Profit Before Tax		137.52B	150.63B
Net Income		109.29B	115.09B
Dil. Shares Diluted Shares		2.40B	2.40B
Diluted EPS		45.60	47.80

Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.

Understanding the Income Statement

The income statement shows Sun Pharma's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.

Sun Pharma Balance Sheet

Hover the chart icon for year-over-year change.

FY 2025 – FY 2026

Item	Chart	2025	2026
Curr. assets Total current assets		526.24B	638.60B
Non-curr. assets Total non-current assets		394.76B	449.25B
Total assets		921.01B	1,087.85B
Curr. liabilities Total current liabilities		181.95B	226.22B
Non-curr. liab. Total non-current liabilities		14.20B	22.83B
Total liabilities		196.15B	249.05B
Total equity		724.86B	838.80B
Total liab. & eq. Total liabilities & equity		921.01B	1,087.85B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding the Balance Sheet

The balance sheet captures Sun Pharma's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.

Sun Pharma Cash Flow Statement

Hover the chart icon for year-over-year change.

FY 2025 – FY 2026

Item	Chart	2025	2026
Net Income		137.52B	151.19B
Operating CF Cash flow Operating Activities		140.72B	124.19B
Capex Investments in PPE		-21.29B	-36.09B
Investing CF Cash flow Investing Activities		-53.06B	-113.44B
Dividend Paid		-36.14B	-39.34B
Financing CF Cash flow Financing Activities		-79.06B	-25.13B
Cash (start) Cash at beginning of period		92.86B	102.69B
Cash (end) Cash at end of period		102.69B	97.71B
FCF Free Cash Flow		119.44B	88.10B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding Cash Flow

The cash flow statement tracks how Sun Pharma's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2026